Portage Biotech (NASDAQ:ALP) Stock Rating Upgraded by Wall Street Zen

Portage Biotech (NASDAQ:ALP) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities analysts have also issued reports on the company. Zacks Research upgraded Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. Finally, HC Wainwright assumed coverage on shares of Portage Biotech in a report on Monday, August 17th. They issued a “neutral” rating and a $12.50 price target on the stock. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $12.50.

Portage Biotech Price Performance

Portage Biotech stock opened at $4.04 on Friday. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01. The firm has a market cap of $6.26 million, a P/E ratio of -0.49 and a beta of 0.54. The business has a fifty day moving average of $10.78 and a two-hundred day moving average of $14.86. Portage Biotech has a twelve month low of $3.20 and a twelve month high of $690.00.

Portage Biotech (NASDAQ:ALP) last released its quarterly earnings results on Thursday, July 16th. The company reported $23.75 EPS for the quarter. The company had revenue of $0.05 million during the quarter. On average, analysts forecast that Portage Biotech will post -14 earnings per share for the current fiscal year.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.